<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Multiple myeloma: Prevention of venous thromboembolism
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Multiple myeloma: Prevention of venous thromboembolism
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Multiple myeloma: Prevention of venous thromboembolism
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Zonder, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles A Schiffer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            S Vincent Rajkumar, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rebecca F Connor, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with multiple myeloma (MM) have an increased incidence of venous thromboembolism (VTE) that appears to be related to both the malignancy itself and the therapy given. In particular, the rate of VTE is especially high for patients with MM treated with regimens that contain an immunomodulatory drug such as
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         , or
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         .
        </p>
        <p>
         Prophylactic strategies to minimize this risk of VTE in patients with MM will be discussed here. Thrombotic risk following the use of other antineoplastics (eg,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , L-asparaginase) and issues related to the treatment of VTE are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1353.html" rel="external">
          "Cancer-associated hypercoagulable state: Causes and mechanisms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8265.html" rel="external">
          "Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">
          "Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H642162558">
         <span class="h1">
          VTE INCIDENCE AND RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H642162566">
         <span class="h2">
          General risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         VTE is the most common form of thrombosis in patients with MM. Arterial thrombotic events have also been reported, although at a lower rate [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Patients with MM are at an increased risk of having comorbidities known to be risk factors for the development of VTE in the general population, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immobilization related to bone involvement and pathologic fractures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney injury, including nephrotic syndrome in some patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes due to glucocorticoid use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute infection due to immunosuppression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central venous catheter placement
        </p>
        <p>
        </p>
        <p>
         Observational studies have also suggested an increased risk of thrombosis among patients with MM who have elevated levels of D-dimer and prothrombin fragments 1 and 2 [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         The impact of these and other risk factors in the general population is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H625282176">
         <span class="h2">
          Immunomodulatory drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of thrombosis among patients with MM taking an immunomodulatory drug (IMiD) varies depending on many factors. In particular, VTE rates are
         <strong>
          higher
         </strong>
         when IMiDs are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Given as induction therapy (high burden of disease)
         </strong>
         – The highest risk of VTE is in the first six months following a new diagnosis of MM. In a meta-analysis of &gt;9000 patients treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , the lowest incidence of VTE was among patients treated with single-agent lenalidomide as maintenance [
         <a href="#rid5">
          5
         </a>
         ]. These individuals had already completed induction therapy and presumably had better disease control than patients receiving combination therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Given in combination with other agents
         </strong>
         – VTE rates are higher when an IMiD is given with
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and/or other agents and lower when used as a single agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Given in combination with an anthracycline
         </strong>
         – VTE rates are very high when IMiDs are combined with an anthracycline [
         <a href="#rid6">
          6-12
         </a>
         ]. As an example, one study of
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         reported VTE in 11 of 19 patients (58 percent) not receiving prophylaxis [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Given with higher-dose
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
          (&gt;160 mg/month)
         </strong>
         – The high VTE risk related to induction therapy with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         without mandated thromboprophylaxis was evident in a phase 3 trial (SWOG 0232), in which 9 of the first 12 patients randomized to this combination developed thromboembolic events (8 lower extremity VTEs and 1 ischemic stroke), prompting modification of the trial to require VTE prophylaxis [
         <a href="#rid13">
          13
         </a>
         ]. The precise impact of dexamethasone dose on VTE risk was illustrated in another phase 3 trial (ECOG E4A03), in which 445 patients with previously untreated MM receiving lenalidomide were randomly assigned to higher-dose dexamethasone (total 480 mg/month) versus lower-dose dexamethasone (total160 mg/month) [
         <a href="#rid14">
          14
         </a>
         ]. The trial was stopped prematurely due to higher mortality in the higher-dose dexamethasone arm; VTE rates were also higher in those assigned to higher-dose dexamethasone (26 versus 12 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Given with erythropoietin
         </strong>
         – In a multivariable analysis of MM-009 and MM-010, concomitant use of recombinant human erythropoietin was an independent contributor to the risk of development of VTE (odds ratio 3.2; 95% CI 1.7-6.0) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Most of these factors have been incorporated into VTE risk stratification scoring systems. (See
         <a class="local">
          'VTE risk stratification scoring systems'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1567676294">
         <span class="h3">
          Lenalidomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MM treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         have an increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as an increased risk of myocardial infarction and stroke. The package insert includes a boxed warning for venous and arterial thromboembolism with a recommendation that all patients receive thromboprophylaxis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The risk of VTE in patients treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         is higher than for those treated with either agent alone. In several randomized trials, the incidence of VTE among those treated with lenalidomide plus high-dose dexamethasone was at least threefold higher than that seen with dexamethasone alone [
         <a href="#rid15">
          15,17-20
         </a>
         ].
        </p>
        <p>
         VTE rates in patients receiving
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         were estimated in a meta-analysis that included data from &gt;9000 patients on clinical trials who received lenalidomide-based treatment regimens that did
         <strong>
          not
         </strong>
         contain high-dose dexamethasone [
         <a href="#rid5">
          5
         </a>
         ]. VTE prophylaxis was unspecified but given to most patients. The pooled rate of VTE was 1.2 VTE events per 100 patient cycles where a cycle represents one month of lenalidomide treatment. The rate differed by regimen and was:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lowest with single-agent
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         maintenance (0.0; 95% CI 0.0-0.7 events per 100 patient cycles)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (0.2; 95% CI 0.1-0.6 events per 100 patient cycles)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and a proteasome inhibitor (&gt;80 percent of patients received
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         or
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ; 1.3; 95% CI 0.7-2.3 events per 100 patient cycles)
        </p>
        <p>
        </p>
        <p>
         The lowest incidence of VTE was among patients who had already completed induction therapy and presumably had better disease control than patients receiving combination therapy. In another report, an expanded access program of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         in 1438 patients with relapsed myeloma that recommended VTE prophylaxis for all enrollees recorded VTE in 3 percent [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Pomalidomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MM treated with
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         have an increased risk of DVT and PE, as well as an increased risk of myocardial infarction and stroke. The package insert includes a boxed warning for venous and arterial thromboembolism with a recommendation that all patients receive thromboprophylaxis [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Without prophylaxis, the rate of VTE is high. In a phase 1 study of single-agent
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         in 24 patients with relapsed or refractory MM, no prophylaxis was administered, and four patients (17 percent) developed VTE [
         <a href="#rid22">
          22
         </a>
         ]. One clot occurred three weeks into therapy in the lower extremity of a patient subsequently recognized as having malignant melanoma-associated adenopathy, whereas the others occurred after 4, 9, and 11 months of pomalidomide therapy.
        </p>
        <p>
         Subsequent trials investigating the use of
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         plus low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         have routinely included thromboprophylaxis with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or other agents [
         <a href="#rid23">
          23-27
         </a>
         ]. Rates of VTE in these trials have been approximately 3 percent.
        </p>
        <p class="headingAnchor" id="H4046537322">
         <span class="h3">
          Thalidomide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MM treated with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         have an increased risk of DVT and PE, as well as an increased risk of myocardial infarction and stroke. The package insert includes a boxed warning for venous thromboembolism with a recommendation to consider thromboprophylaxis in all patients [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         The risk of VTE among patients with MM taking single-agent
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         does not appear to be increased over that of patients with MM not taking thalidomide. In contrast, the risk of VTE increases substantially when thalidomide is administered in conjunction with glucocorticoids or other agents (eg,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , erythropoietin) [
         <a href="#rid29">
          29
         </a>
         ]. While the majority of thrombotic events described in patients treated with thalidomide have been venous, arterial thrombotic events have also been reported [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Single-agent
         </strong>
         <strong>
          thalidomide
         </strong>
         – The thrombosis incidence of approximately 1 to 5 percent in trials using single-agent
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         is similar to the background rate of such events in patients with MM not receiving treatment with this agent [
         <a href="#rid6">
          6,30-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thalidomide
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          dexamethasone
         </strong>
         – The reported frequency of thrombotic events has been as high as 26 percent when
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         is used in combination with high-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (TD) [
         <a href="#rid6">
          6,32,37-40
         </a>
         ]. As an example, in one randomized trial, DVT occurred in 17 of 102 patients (17 percent) treated with TD versus 3 of 102 patients (3 percent) treated with dexamethasone alone [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thalidomide
         </strong>
         <strong>
          , steroid, plus an alkylating agent
         </strong>
         – The risk of VTE during treatment with the combination of
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , steroids, and an alkylating agent (
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) is similar to that seen following the use of thalidomide and steroids alone [
         <a href="#rid6">
          6,41-45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thalidomide
         </strong>
         <strong>
          , steroid, plus an anthracycline
         </strong>
         – Regimens utilizing
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         in combination with an anthracycline appear to be associated with the highest risk of VTE [
         <a href="#rid6">
          6-12
         </a>
         ]. As an example, one study of thalidomide,
         <a class="drug drug_general" data-topicid="10135" href="/z/d/drug information/10135.html" rel="external">
          pegylated liposomal doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         reported VTE in 11 of 19 patients (58 percent) not receiving prophylaxis (though the mandated VTE surveillance strategy utilized in this trial likely affected the observed rate of VTE) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1205054485">
         <span class="h2">
          Proteasome inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of VTE in patients receiving a proteasome inhibitor appears to depend on the proteasome inhibitor used. The risk appears to be increased with
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         but not with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         or
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         . As such, the package insert for carfilzomib includes a recommendation for thromboprophylaxis, whereas the package inserts for bortezomib and ixazomib do not [
         <a href="#rid46">
          46-48
         </a>
         ].
        </p>
        <p>
         In a meta-analysis that included patients treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus low-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         and included VTE prophylaxis, the addition of a proteasome inhibitor increased the rate of VTE events from 0.2 events per 100 patient cycles to 1.3 events per 100 patient cycles [
         <a href="#rid5">
          5
         </a>
         ]. However, the proteasome inhibitor used in &gt;80 percent of patients in this meta-analysis was
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         or
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Carfilzomib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          lenalidomide
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          dexamethasone
         </strong>
         – Randomized trials have reported increased VTE rates when
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         was added to
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (13 versus 6 percent in ASPIRE [
         <a href="#rid49">
          49
         </a>
         ]) and higher VTE rates with carfilzomib plus dexamethasone when compared with
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         plus dexamethasone (9 versus 2 percent in ENDEAVOR [
         <a href="#rid50">
          50
         </a>
         ]). A retrospective study reported VTE rates with carfilzomib, lenalidomide, and dexamethasone (KRd) plus
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (16.1 percent); bortezomib, lenalidomide, and dexamethasone (VRd) plus aspirin (4.8 percent); and KRd plus
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         (4.8 percent) suggesting that KRd is more prothrombotic than VRd and that more intensive prophylaxis with rivaroxaban may be able to counteract this increased VTE rate [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bortezomib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          lenalidomide
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          dexamethasone
         </strong>
         <strong>
         </strong>
         – Randomized trials evaluating the addition of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         to
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         or
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         plus dexamethasone did not demonstrate an increase in VTE rates over that seen with the doublets alone [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ixazomib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          lenalidomide
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          dexamethasone
         </strong>
         – In a placebo controlled trial that mandated thromboprophylaxis, the addition of
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         to
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         did not increase the rate of thromboembolism (8 percent with ixazomib, lenalidomide, and dexamethasone and 11 percent with lenalidomide and dexamethasone) [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1791783695">
         <span class="h2">
          Monoclonal antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with MM, the risk of VTE does not appear to increase with the addition of a monoclonal antibody (ie,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="127258" href="/z/d/drug information/127258.html" rel="external">
          isatuximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="105610" href="/z/d/drug information/105610.html" rel="external">
          elotuzumab
         </a>
         ).
        </p>
        <p>
         In one meta-analysis that included six trials, regimens that included
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         were associated with a lower risk of VTE compared with regimens that did not include daratumumab (risk ratio 0.60; 95% CI 0.40-0.91) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Similarly, a post-hoc analysis of the phase 2 GRIFFIN study did not show an increase in VTE with the addition of
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         to
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (10 percent with daratumumab with lenalidomide, bortezomib, and dexamethasone versus 16 percent with lenalidomide, bortezomib, and dexamethasone) [
         <a href="#rid56">
          56
         </a>
         ]. While the protocol recommended VTE prophylaxis, thromboprophylaxis use and adherence were suboptimal, potentially explaining the higher-than-expected VTE rate.
        </p>
        <p class="headingAnchor" id="H2843962329">
         <span class="h1">
          VTE RISK STRATIFICATION SCORING SYSTEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sections that follow describe several scoring systems that have been developed to incorporate risk factors for VTE in patients with MM and have demonstrated the ability to differentiate risk. In contrast, the International Myeloma Working Group (IMWG) risk stratification score and Khorana scores appear to be poor predictors of VTE risk in patients with MM, so they are less clinically helpful [
         <a href="#rid6">
          6,57-59
         </a>
         ].
        </p>
        <p>
         The impact of various risk factors on the development of VTE in the general population is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3364305760">
         <span class="h2">
          SAVED score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The SAVED score predicts the risk of VTE in patients with MM receiving an immunomodulatory drug (IMiD; ie,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ). It has not been validated in other populations. A SAVED score ≥2 points designates high VTE risk  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         The acronym SAVED can assist with remembering the factors included in score calculation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         S – Surgery within 90 days (+2 points)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A – Asian population (-3 points)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         V – VTE history (+3 points)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         E – Elders: Age ≥80 years (+1 point)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D –
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         &gt;160 mg/month (+2 points) or 120 to 160 mg/month (+1 point)
        </p>
        <p>
        </p>
        <p>
         The SAVED score was derived using data from &gt;2300 patients with MM within the SEER-Medicare database and validated using &gt;1200 patients with MM included in the Veterans Administration Central Cancer Registry [
         <a href="#rid58">
          58
         </a>
         ]. The databases did not include information regarding use of over-the-counter
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         . Also, the study was limited to patients treated prior to 2014, so they were not exposed to drugs approved after that time (eg,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ). In the validation cohort, VTE occurred in 9.4 percent within 12 months of starting an IMiD. Patients with a SAVED score ≥2 points had a higher incidence of VTE after starting an IMiD at three months (6 versus 4 percent), six months (11 versus 7 percent), and 12 months (16 versus 8 percent; overall hazard ratio 1.98).
        </p>
        <p>
         In another validation cohort that included &gt;500 patients starting an IMiD (95 percent received
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for thromboprophylaxis), the percent with VTE within six months increased with the SAVED score: 0 points (2.7 percent), 1 point (8.7 percent), 2 points (26.7 percent), and ≥3 points (35.4 percent) [
         <a href="#rid60">
          60
         </a>
         ]. The higher rates of VTE in the validation cohort compared with the derivation cohort likely reflect the study design, including the exclusion of patients on single-agent maintenance therapy and the use of chart review for data extraction.
        </p>
        <p>
         The SAVED score compared favorably versus the National Comprehensive Cancer Network/IMWG model, which was unable to adequately discriminate VTE risk in this population [
         <a href="#rid6">
          6,58
         </a>
         ]. Interpretation of the SAVED score must take into account its retrospective design, limited data regarding
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use, and lack of treatments approved after 2014 (eg,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ). Also, while ethnicity/race is included in the score, the dataset had few females and persons of Asian descent, limiting interpretation in these populations. However, despite the limitations of the methodology used in the original SAVED score publication, the utility of this scoring system was confirmed by the external validation cohort, which used slightly different methodology for identifying VTEs.
        </p>
        <p class="headingAnchor" id="H1861706325">
         <span class="h2">
          IMPEDE VTE score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The IMPEDE VTE score predicts the risk of VTE in patients with MM treated with or without IMiDs. If the IMPEDE VTE score is used for clinical VTE risk assessment, we propose using a cutoff of ≥8 points to designate high VTE risk  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ). This cutoff predicts a VTE risk that is similar to that with a SAVED score of ≥2 points and more clearly identifies patients who need prophylaxis that is more intensive than
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         alone. Some other experts use an IMPEDE VTE score ≥4 points to designate high VTE risk [
         <a href="#rid57">
          57,61
         </a>
         ].
        </p>
        <p>
         The acronym IMPEDE VTE can assist with remembering the factors included in score calculation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         I –
         <strong>
          I
         </strong>
         mmunomodulatory drug (+4 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         M – Body
         <strong>
          m
         </strong>
         ass index ≥25 kg/m
         <sup>
          2
         </sup>
         (
         <a class="calc calc_professional" href="/z/d/html/13478.html" rel="external">
          calculator 1
         </a>
         )(+1 point)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         P –
         <strong>
          P
         </strong>
         elvic, hip, or femur fracture (+4 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         E –
         <strong>
          E
         </strong>
         rythropoiesis-stimulating agent (+1 point)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D –
         <strong>
          D
         </strong>
         oxorubicin or multiagent chemotherapy (+3 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         D –
         <strong>
          D
         </strong>
         examethasone &gt;160 mg/month (+4 points) or &lt;160 mg/month (+2 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         E –
         <strong>
          E
         </strong>
         thnicity/race is Asian/Pacific Islander (-3 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         V – History of
         <strong>
          V
         </strong>
         TE before diagnosis of MM (+5 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T –
         <strong>
          T
         </strong>
         unneled central line or central venous catheter (+2 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         E –
         <strong>
          E
         </strong>
         xisting thromboprophylaxis with prophylactic dose low molecular weight heparin or
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (-3 points) or therapeutic dose low molecular weight heparin or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (-4 points)
        </p>
        <p>
        </p>
        <p>
         The IMPEDE VTE score was derived using data from &gt;4400 patients with MM within the Veterans Administration Central Cancer Registry and validated using &gt;4200 patients with MM included in the SEER-Medicare database [
         <a href="#rid57">
          57
         </a>
         ]. The databases did not include data regarding use of over-the-counter
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         . Also, patients were treated prior to 2014, so they were not exposed to drugs approved after that time (eg,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ).
        </p>
        <p>
         The six-month cumulative incidence of VTE after starting therapy in the validation cohort was 5.2 percent, and the hazard ratio for VTE increased by 1.16 per point. Three risk groups could be determined based on the cumulative score with significantly different six-month cumulative incidence rates of VTE from the start of chemotherapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≤3 points – 3.3 percent (95% CI 2.6-4.1)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         4 to 7 points – 8.3 percent (95% CI 7.1-9.8)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥8 points – 15.2 percent (95% CI 12.1-19)
        </p>
        <p>
        </p>
        <p>
         This model was able to better discriminate VTE risk when compared with a previous National Comprehensive Cancer Network/IMWG model [
         <a href="#rid6">
          6,57
         </a>
         ]. However, study limitations include its retrospective design and limited data regarding
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use. Also, while ethnicity/race is included in the score, the dataset used to derive and validate IMPEDE VTE included few females and persons of Asian or Pacific Islander descent, limiting interpretation in these populations. Finally, it is not known whether VTE risk might be impacted by agents approved after the study period (eg,
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105607" href="/z/d/drug information/105607.html" rel="external">
          ixazomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1071781686">
         <span class="h2">
          PRISM score
         </span>
         <span class="headingEndMark">
          —
         </span>
         The PRISM score was developed to predict the risk of VTE in outpatients with MM treated with or without immunomodulatory agents. The score was developed based on a relatively small cohort of patients, and we await further validation before incorporating it into routine practice.
        </p>
        <p>
         The acronym PRISM can assist with remembering the factors included in score calculation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         P – Prior VTE (+8 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         R – Black American (+1 point)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         I – Immunomodulatory drug use (+2 points)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         S – Surgery within 90 days (+5 points), excludes minimally invasive procedures such as kyphoplasty or vertebroplasty
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         M – Abnormal metaphase cytogenetics (+2 points)
        </p>
        <p>
        </p>
        <p>
         The PRISM score was derived using individual patient-level data from a cohort of &gt;780 patients with MM diagnosed at the Cleveland Clinic between 2008 and 2018 and validated with a separate cohort of &gt;200 patients with MM from Columbia University [
         <a href="#rid62">
          62
         </a>
         ]. In the derivation and validation cohorts, the most common induction regimen used was
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         (41 percent) with a monthly dexamethasone dose of 120 to 160 mg (76 percent). Most patients received thromboprophylaxis with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (60 percent) or prophylactic low molecular weight heparin (4 percent). In the derivation cohort, the cumulative incidence of VTE at 6 and 12 months was 8.2 and 11.5 percent. In contrast, the incidence of VTE in the validation cohort was low (23 events within one year).
        </p>
        <p>
         The risk of VTE increased with each point by a hazard ratio of 1.28, and patients could be divided into three risk groups with significantly different cumulative VTE incidence at 12 months:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low risk (score 0) – 2.7 percent (95% CI 0.7-7.0)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate risk (score 1 to 6) – 10.8 percent (95% CI 8.2-13.8)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High risk (score ≥7) – 36.5 percent (95% CI 23.6-49.6)
        </p>
        <p>
        </p>
        <p>
         In this study, development of a VTE within 12 months of starting therapy did not impact overall survival.
        </p>
        <p class="headingAnchor" id="H3063822236">
         <span class="h1">
          VTE PROPHYLAXIS INDICATIONS AND DURATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with MM should have an assessment of their VTE risk so that appropriate prophylaxis may be employed  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ). VTE prophylaxis is a standard part of the treatment of patients with MM unless there are contraindications to anticoagulation agents or antiplatelet agents. We use a risk-stratified approach that is generally consistent with recommendations from the International Myeloma Working Group; the National Comprehensive Cancer Network; the International Initiative on Thrombosis and Cancer; the American Society of Hematology; and the American Society of Clinical Oncology [
         <a href="#rid6">
          6,61,63-66
         </a>
         ].
        </p>
        <p>
         VTE prophylaxis is generally administered as long as active therapy is continued [
         <a href="#rid6">
          6
         </a>
         ]. It is not known whether VTE prophylaxis can be safely discontinued in patients receiving prolonged therapy with immunomodulatory drug (IMiD)-containing regimens. The risk of VTE appears to be greatest in the first 6 to 12 months of treatment. The risk appears to decrease after this and is lower among patients treated for relapsed disease than for patients with previously untreated MM.
        </p>
        <p>
         VTE rates are increased in patients with MM treated with a regimen that includes an IMiD (eg,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ) and/or
         <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">
          carfilzomib
         </a>
         . Without thromboprophylaxis, VTE rates in these populations can exceed 20 percent. In comparison, the rate of VTE decreases to less than 10 percent when VTE prophylaxis is administered (in the absence of other risk factors for VTE beyond IMiD use). In a meta-analysis that included data from &gt;9000 patients on clinical trials who received thromboprophylaxis along with a lenalidomide-based treatment regimen that did not contain high-dose
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , the pooled rate of VTE was 1.2 (95% CI 0.9-1.7) VTE events per 100 patient cycles where a cycle represents one month of lenalidomide treatment [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         There are no randomized trials comparing treatment with or without VTE prophylaxis; most of the data consist of comparisons of single-arm trials with historical controls in which prophylaxis was not used. Numerous variables can influence such nonrandomized studies.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          CHOICE OF VTE PROPHYLAXIS
         </span>
        </p>
        <p class="headingAnchor" id="H1620334737">
         <span class="h2">
          During induction therapy
         </span>
        </p>
        <p class="headingAnchor" id="H642163521">
         <span class="h3">
          Risk stratification
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients receiving induction therapy for MM, our preferred thromboprophylaxis depends on  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The baseline risk of VTE associated with a given regimen
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence or absence of additional risk factors for thromboembolism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The risk of bleeding complications from VTE prophylaxis
        </p>
        <p>
        </p>
        <p>
         Those already on therapeutic anticoagulation for another indication (eg, atrial fibrillation) should continue their prior anticoagulation. We reassess VTE risk, bleeding risk, and prophylaxis choice periodically. Patients may shift from one group to another if complications arise or treatment is de-escalated.
        </p>
        <p>
         A validated risk stratification scoring system can be used to estimate VTE risk. Cutoff values to identify high VTE risk include a SAVED score ≥2 or an IMPEDE VTE score ≥8. (See
         <a class="local">
          'VTE risk stratification scoring systems'
         </a>
         above.)
        </p>
        <p>
         For patients treated with an immunomodulatory drug (IMiD), we prefer SAVED for its simplicity and because it more clearly identifies patients who might benefit from prophylaxis that is more intensive than
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         alone. (See
         <a class="local">
          'SAVED score'
         </a>
         above.)
        </p>
        <p>
         For patients treated without an IMiD, we use IMPEDE VTE as SAVED has not been validated in this population. If the IMPEDE VTE score is used for clinical VTE risk assessment, we propose using a cutoff of ≥8 points to designate high VTE risk. This cutoff predicts a VTE risk that is similar to that with a SAVED score of ≥2 points. (See
         <a class="local">
          'IMPEDE VTE score'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H642162822">
         <span class="h3">
          Standard VTE risk (aspirin preferred)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with standard VTE risk (eg, a SAVED score &lt;2 or IMPEDE VTE score &lt;8), we suggest VTE prophylaxis with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         100 to 325 mg daily rather than anticoagulation with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , low molecular weight heparin (LMWH), or a direct oral anticoagulant  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ). A common example of standard VTE risk is a patient without other risk factors being treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         , and weekly
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         . We reassess VTE risk, bleeding risk, and prophylaxis choice periodically. Patients with standard VTE risk may shift to having a high VTE risk if complications arise.
        </p>
        <p>
         This preference is largely based on the lower cost and ease of administration of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and randomized trials that demonstrated similar rates of serious thromboembolic events compared with other low-intensity VTE prophylaxis options (namely fixed-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         or low-dose LMWH) [
         <a href="#rid67">
          67,68
         </a>
         ]. In our practice, almost all patients are able to tolerate aspirin when administered with appropriate gastrointestinal prophylaxis (eg, an H2-blocker or a proton pump inhibitor).
        </p>
        <p>
         An open-label phase 3 trial of 667 patients receiving thalidomide-containing induction therapy randomly assigned VTE prophylaxis with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         100 mg daily, fixed low-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         1.25 mg daily, or LMWH (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg once daily) [
         <a href="#rid67">
          67
         </a>
         ]. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of a composite endpoint of serious thromboembolic events (symptomatic deep vein thrombosis [DVT], pulmonary embolism, or arterial thrombosis), acute cardiovascular events (myocardial infarction or stroke), and sudden death during the first six months of therapy was not significantly different in the three groups (6.4, 8.2, and 5.0 percent, respectively), although the trial was not powered to detect a difference as large as 3.2 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There was no statistically or clinically significant difference in adverse events. Major bleeding occurred during the first six months in three patients who received
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         but in no patients who received
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         or LMWH. Minor bleeding occurred in 2.7, 0.5, and 1.4 percent of patients, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of serious thromboembolic events was lower with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and low-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         than rates reported with these agents in other trials. In comparison, the rate of thromboembolism with LMWH was similar to that reported in other trials.
        </p>
        <p>
        </p>
        <p>
         In a second phase 3 trial, 342 adults were randomly assigned to VTE prophylaxis with either
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         100 mg/day or LMWH (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg daily) during treatment with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         or
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and lenalidomide [
         <a href="#rid68">
          68
         </a>
         ]. When compared with LMWH, low-dose aspirin resulted in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A similar incidence of the primary composite endpoint of confirmed symptomatic DVT, pulmonary embolism, arterial thrombosis, any acute cardiovascular event, or sudden otherwise unexplained death in the first six months after random assignment (2.27 versus 1.20 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A similar rate of confirmed symptomatic DVT (1.14 versus 1.20 percent). All three cases of pulmonary embolism occurred in the aspirin-treated group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There were no acute cardiovascular events, arterial thromboses, or sudden deaths in either group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There were no major bleeding episodes in either group. The one minor bleeding episode (gastrointestinal bleeding) was seen in a patient receiving LMWH.
        </p>
        <p>
        </p>
        <p>
         These trials suggest that low, fixed-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , prophylactic-dose LMWH, and low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         are all acceptable choices of VTE prophylaxis in patients with standard VTE risk. All three options lowered the incidence of VTE to less than 5 percent compared with an expected rate of more than 20 percent. It is unknown how these regimens would compare with VTE prophylaxis with therapeutic adjusted-dose warfarin (international normalized ratio [INR] 2.0 to 3.0) or therapeutic-dose LMWH. Use of aspirin is simpler and less expensive than LMWH. Of importance, these trials excluded patients thought to be at higher risk of thromboembolic events due to a history of VTE, severe cardiac disease, immobilization, uncontrolled diabetes, recent surgery, or ongoing infections. Such patients should be considered for more intensive VTE prophylaxis. (See
         <a class="local">
          'High VTE risk'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H642162830">
         <span class="h3">
          High VTE risk
         </span>
        </p>
        <p class="headingAnchor" id="H3250977896">
         <span class="h4">
          Anticoagulation versus aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with high VTE risk (eg, a SAVED score ≥2 or an IMPEDE VTE score ≥8), we suggest VTE prophylaxis with LMWH, a direct oral anticoagulant (DOAC), or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         rather than
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ). However, data on VTE prophylaxis in this setting are limited, and clinical practice varies widely. Aspirin is an acceptable alternative, especially for patients at high risk of bleeding complications with anticoagulation. We reassess VTE risk, bleeding risk, and prophylaxis choice periodically. Patients with a high VTE risk may transition to having a low VTE risk as treatment is de-escalated and disease control is achieved.
        </p>
        <p>
         Details regarding the specific agents are described below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prophylactic- or therapeutic-dose LMWH (see
         <a class="local">
          'Low molecular weight heparin'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapeutic-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         with a target INR of 2.0 to 3.0 (see
         <a class="local">
          'Warfarin'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prophylactic-dose DOAC (see
         <a class="local">
          'Direct oral anticoagulants'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Our preference for more intensive anticoagulation over
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         is largely based upon data suggesting efficacy of full-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and LMWH and the uncertainty regarding the efficacy of aspirin in this setting. Prophylactic-dose LMWH may be preferred over full anticoagulation in patients at higher risk for bleeding complications, whereas therapeutic doses may be preferred for those receiving intensive, anthracycline-containing therapy in conjunction with an IMiD. (See
         <a class="local">
          'Patients at high risk of bleeding'
         </a>
         below.)
        </p>
        <p>
         The choice between LMWH, DOAC, and
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         is made based upon the clinical circumstances. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LMWH may be preferred in patients who are likely to develop thrombocytopenia (such as those receiving chemotherapy) because of its short half-life and suggested lower risk of secondary bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         might be preferred in patients with an estimated glomerular filtration rate below 30 mL/min. If LMWH (eg,
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ) is given to patients with kidney impairment, dose reduction is suggested  (
         <a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and DOACs have drug interactions that may necessitate dose adjustments, as detailed in the
         <a class="external" href="/drug-interactions/">
          drug interactions program
         </a>
         within UpToDate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          Warfarin
         </a>
         and DOACs differ in their dosing frequency, dietary restrictions, need for monitoring, drug interactions, and availability of antidotes in the case of excessive bleeding  (
         <a class="graphic graphic_table graphicRef91199" href="/z/d/graphic/91199.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3526427548">
         <span class="h4">
          Low molecular weight heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of prophylactic doses of LMWH (eg,
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg/day subcutaneously [SQ]) appears to reduce the frequency of thrombotic events in patients with MM receiving immunomodulatory therapy. A number of LMWH preparations are available, none of which have proven superiority over the other. Dosing for thromboprophylaxis, including adjustments for body weight and kidney function, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Dosing'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of 400 patients, the incidence of VTE among patients at high risk for VTE treated with a thalidomide-containing regimen plus daily LMWH prophylaxis was not statistically different from that seen in patients treated with a chemotherapy regimen that did not contain
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         and who were not given VTE prophylaxis (9 versus 5 percent) [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         with or without
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , the first 65 patients assigned to treatment with thalidomide did not receive prophylaxis and had an incidence of VTE of 20 percent [
         <a href="#rid43">
          43
         </a>
         ]. The next 64 patients received thromboprophylaxis with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg/day SQ for the first four cycles (months) of therapy, with an incidence of VTE of 3.1 percent. Two patients developed VTE within two months of discontinuation of enoxaparin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of induction chemotherapy with
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , followed by autologous hematopoietic cell rescue and maintenance interferon, each phase given with or without
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         therapy, the addition of thalidomide without prophylaxis increased the incidence of VTE (34 versus 18 percent) [
         <a href="#rid70">
          70
         </a>
         ]. The rate of VTE was still concerningly high after protocol adjustments included prophylactic LMWH for those receiving thalidomide (24 percent). These results suggest a role for therapeutic-dose LMWH in patients undergoing such intensive, anthracycline-containing therapy in conjunction with an IMiD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A single-institution retrospective study reported that only 1 in 45 patients with relapsed refractory MM treated with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         given in conjunction with LMWH developed VTE [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although the data are mixed, these results suggest that, in the absence of intensive, anthracycline-containing therapy, LMWH decreases the rate of VTE among the patients treated with IMiD-containing regimens to less than 10 percent.
        </p>
        <p class="headingAnchor" id="H892776034">
         <span class="h4">
          Warfarin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Full-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , with a target INR of 2.0 to 3.0, may be used for VTE prophylaxis in patients with MM being treated with IMiD combinations who are at high risk of VTE. Warfarin has drug interactions that may necessitate dose adjustments, as detailed in the
         <a class="external" href="/drug-interactions/">
          drug interactions program
         </a>
         within UpToDate.
        </p>
        <p>
         Support for the use of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         comes from small observational studies and retrospective reviews that suggest a potential benefit of full-intensity anticoagulation with warfarin, in comparison to a fixed low-dose warfarin:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, VTE developed in 34 percent of 162 patients receiving induction chemotherapy plus
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         despite VTE prophylaxis with fixed-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         1 mg/day [
         <a href="#rid33">
          33,70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second report, the incidence of VTE with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         plus
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         decreased when VTE prophylaxis was changed from fixed, low-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (6 of 24 patients, 25 percent) to full-dose warfarin or LMWH (none of 16 patients) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective review of 131 patients treated with
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         , VTE was noted in 18 of 76 patients (24 percent) not receiving anticoagulation and 3 of 55 patients (5 percent) receiving either low-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         (1 of 37, 3 percent) or conventional-dose warfarin (2 of 18, 11 percent) [
         <a href="#rid72">
          72
         </a>
         ]. The effectiveness of low-dose warfarin in this report may be explained by the lower mean/median dose of thalidomide (average 200 mg/day) used in these patients, although there are no data clearly demonstrating a dose-effect relationship for thalidomide and thrombosis risk.
        </p>
        <p>
        </p>
        <p>
         There are limited data on the use of therapeutic-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         in patients treated with IMiDs other than
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         . In one small, retrospective study, there were no clinically significant VTEs among a cohort of 13 patients with lenalidomide-treated MM who developed asymptomatic VTE of the lower extremity and were treated with therapeutic-dose warfarin [
         <a href="#rid73">
          73
         </a>
         ]. While this was a very small cohort, such patients would be at a higher risk for clinically significant VTE than unselected patients.
        </p>
        <p class="headingAnchor" id="H278383581">
         <span class="h4">
          Direct oral anticoagulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are limited data regarding the use of DOACs (direct thrombin inhibitors or factor Xa inhibitors) as VTE prophylaxis in patients receiving IMiD-containing therapy [
         <a href="#rid74">
          74-77
         </a>
         ]. DOACs have drug interactions that may necessitate dose adjustments, as detailed in the
         <a class="external" href="/drug-interactions/">
          drug interactions program
         </a>
         within UpToDate.
        </p>
        <p>
         A nonrandomized phase 2 study evaluated the use of prophylactic-dose
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         in 104 patients with MM receiving
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         ,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         as initial therapy or
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         and
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         for relapsed disease [
         <a href="#rid74">
          74
         </a>
         ]. Two DVTs were observed; both were in patients treated with lenalidomide and dexamethasone, and one occurred while apixaban was being held for thrombocytopenia. There was one nonfatal major hemorrhage and 11 clinically relevant, nonmajor bleeding events.
        </p>
        <p>
         Only 15 patients with MM (2.6 percent) were included in the randomized AVERT trial that compared
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         versus placebo in ambulatory patients with cancer [
         <a href="#rid78">
          78
         </a>
         ]; apixaban decreased rates of VTE (4.2 versus 10.2 percent) and increased major bleeding (3.5 versus 1.8 percent). Patients with MM were excluded from the CASSINI trial of
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         , another trial involving ambulatory cancer patients at high risk for VTE [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         The use of DOACs for VTE prophylaxis in other settings is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1352.html" rel="external">
          "Risk and prevention of venous thromboembolism in adults with cancer", section on 'Outpatients (VTE prophylaxis)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1312210010">
         <span class="h2">
          During maintenance therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with MM receiving an IMiD (
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         , or
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ) as a single agent for maintenance therapy, including those post-autologous transplantation, we suggest low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis (ie, 81 to 325 mg daily) rather than no prophylaxis or the use of other agents  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ). In our practice, almost all patients are able to tolerate low-dose aspirin when administered with appropriate gastrointestinal prophylaxis (eg, an H2-blocker or a proton pump inhibitor). (See
         <a class="local">
          'VTE prophylaxis indications and duration'
         </a>
         above.)
        </p>
        <p>
         A 2008 International Myeloma Working Group guideline on the prevention of thalidomide- and lenalidomide-associated thrombosis in MM allows for the omission of VTE prophylaxis in this population if the risks of daily
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         are felt to outweigh the small absolute reduction in expected risk of thrombosis [
         <a href="#rid6">
          6
         </a>
         ]. Our preference for aspirin places a higher value on a potentially small absolute decrease in the rate of VTE and less concern about the potential for aspirin-related toxicity. There is less information about the safety of aspirin omission since VTE prophylaxis has been incorporated into most modern trials containing IMiDs, including all trials of
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         .
        </p>
        <p>
         These patients are at a lower risk for VTE than patients receiving combination therapy for active MM, and the absolute benefit from prophylaxis is likely to be smaller. Estimates suggest the rate of thrombosis in this population is similar to the background rate of VTE in patients with MM not receiving treatment with one of these agents (1 to 5 percent) [
         <a href="#rid6">
          6,30-36
         </a>
         ]. Randomized trials of
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         maintenance after transplant that included data from &gt;1000 patients have reported VTE rates up to 6 percent without prophylaxis and &lt;1 percent with prophylaxis (mostly
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ) [
         <a href="#rid80">
          80,81
         </a>
         ]. In one meta-analysis of studies in which the majority of patients received VTE prophylaxis, patients who were taking single-agent lenalidomide maintenance had low estimated rates of VTE (0.0 VTE events per 100 patient cycles; 95% CI 0.0-0.7) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3338248372">
         <span class="h2">
          Adjustments for hospitalization or surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with MM who are hospitalized or undergoing surgery may need modifications to their VTE prophylaxis regimen. Specific recommendations for the prevention of VTE in cancer patients who are hospitalized or are undergoing surgery are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Selection of method of prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1868560884">
         <span class="h2">
          Patients at high risk of bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are at high risk of complications due to bleeding on anticoagulation may not be candidates for pharmacologic VTE prophylaxis. This includes patients with a known bleeding lesion, such as a peptic ulcer, or a recent intracranial hemorrhage.
        </p>
        <p>
         Mechanical methods of thromboprophylaxis, such as graduated compression stockings, intermittent pneumatic compression devices, and the venous foot pump, reduce stasis within the leg veins and reduce the frequency of VTE in other patient populations. Such methods may be considered for hospitalized patients at standard or high risk of VTE who are also at high risk of complications from bleeding on anticoagulation.
        </p>
        <p>
         When used in all of these circumstances, we advise frequent reassessment of risk so that pharmacologic agents can be used when the bleeding risk becomes acceptably low or when the bleeding lesion or bleeding risk has been reversed [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Mechanical methods of thromboprophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H642162936">
         <span class="h1">
          DIAGNOSIS AND MANAGEMENT OF VTE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of VTE is suspected in patients who develop calf or thigh pain, unilateral edema, or swelling with a difference in calf diameters; warmth, tenderness, or erythema of the skin, and/or superficial venous dilation; a palpable cord; chest pain, shortness of breath, or tachycardia. The diagnosis of VTE is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1351.html" rel="external">
          "Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">
          "Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"
         </a>
         .)
        </p>
        <p>
         The management of VTE in patients with MM is similar to the management of VTE in the cancer population. Therapeutic (full-dose) anticoagulation is indicated for patients with VTE and should be started immediately. Agent selection and dosing is described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">
          "Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"
         </a>
         .)
        </p>
        <p>
         There have been no studies investigating whether the immunomodulatory drug (IMiD;
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          thalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         ,
         <a class="drug drug_general" data-topicid="88099" href="/z/d/drug information/88099.html" rel="external">
          pomalidomide
         </a>
         ) should be temporarily held at the time of VTE diagnosis while therapeutic anticoagulation is being achieved. Given their prothrombotic effects, we suggest holding these agents until therapeutic anticoagulation is achieved.
        </p>
        <p>
         For patients with VTE, therapeutic anticoagulation should be continued for the total duration of IMiD therapy. If there have been no further VTE episodes while receiving one of these agents plus therapeutic anticoagulation, we suggest that anticoagulation be stopped one to three months after these agents have been discontinued, provided that the patient has received therapeutic anticoagulation for a minimum of three to six months. This differs somewhat from general recommendations related to the duration of anticoagulation for VTE in cancer patients, in which longer (or indefinite) anticoagulation is common. Since stoppage of the IMiD modifies the overall VTE risk of the patient, we feel that indefinite anticoagulation should be considered only in myeloma patients who have recurrent VTE. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"
         </a>
         .)
        </p>
        <p>
         Patients who developed a prior IMiD-associated VTE being started on another IMiD-containing regimen should be considered at higher risk for developing another thromboembolic event. As such, in our own practice, such patients generally receive at least prophylactic low molecular weight heparin, with some patients being treated with full-dose anticoagulation. The choice between these approaches is made on a case-by-case basis, taking into account perceived bleeding risk and whether there are/were other risk factors for thrombosis in each instance of IMiD use.
        </p>
        <p class="headingAnchor" id="H1473335009">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">
          "Society guideline links: Multiple myeloma"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scope of risk and importance of prophylaxis
         </strong>
         – Patients with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) related to both the malignancy itself and the therapy given. VTE prophylaxis is a standard part of treatment unless there are contraindications to anticoagulation agents or antiplatelet agents. (See
         <a class="local">
          'VTE prophylaxis indications and duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          During induction therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risk stratification
         </strong>
         – For patients receiving induction therapy for MM, our preferred thromboprophylaxis depends on  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The baseline risk of VTE associated with a given regimen
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The presence or absence of additional risk factors for thromboembolism
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The risk of bleeding complications from VTE prophylaxis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We use a SAVED score ≥2 or an IMPEDE VTE score ≥8 to identify patients with high VTE risk. (See
         <a class="local">
          'VTE risk stratification scoring systems'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients treated with an immunomodulatory drug (IMiD), we prefer SAVED for its simplicity and because it more clearly identifies a higher risk population. (See
         <a class="local">
          'SAVED score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients treated without an IMiD, we use IMPEDE VTE, as SAVED has not been validated in this population. (See
         <a class="local">
          'IMPEDE VTE score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We reassess VTE risk, bleeding risk, and prophylaxis choice periodically. Patients may shift from one group to another if complications arise or treatment changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Standard VTE risk (
         </strong>
         <strong>
          aspirin
         </strong>
         <strong>
          preferred)
         </strong>
         – For patients with standard VTE risk (eg, a SAVED score &lt;2 or IMPEDE VTE score &lt;8), we suggest VTE prophylaxis with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         100 to 325 mg daily rather than anticoagulation with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , low molecular weight heparin (LMWH), or a direct oral anticoagulant (DOAC)  (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         is simple and inexpensive and appears to result in similar rates of serious thromboembolic events in this population. In our practice, almost all patients are able to tolerate aspirin when administered with appropriate gastrointestinal prophylaxis (eg, an H2-blocker or a proton pump inhibitor). (See
         <a class="local">
          'Standard VTE risk (aspirin preferred)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High VTE risk (anticoagulation preferred)
         </strong>
         – For patients with high VTE risk (eg, a SAVED score ≥2 or an IMPEDE VTE score ≥8), we suggest VTE prophylaxis with LMWH, a DOAC, or
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         rather than
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef122682" href="/z/d/graphic/122682.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). A choice among these is based on clinical circumstances. (See
         <a class="local">
          'Anticoagulation versus aspirin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This preference is based on data suggesting efficacy of full-dose
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         and LMWH and the uncertainty regarding the efficacy of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in this setting. However, aspirin is an acceptable alternative, especially for patients at high risk of bleeding complications with anticoagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          During maintenance therapy
         </strong>
         – Patients receiving an IMiD as a single agent
         <strong>
         </strong>
         are at a lower risk for VTE. For these patients, we suggest prophylaxis with
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         rather than no prophylaxis or the use of other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'During maintenance therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with VTE
         </strong>
         – The diagnosis and initial management of VTE in patients with MM is similar to that in the larger cancer population. (See
         <a class="local">
          'Diagnosis and management of VTE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who develop VTE and continue treatment with an IMiD, we suggest that therapeutic anticoagulation continue for at least one to three months after completion of treatment with the IMiD (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If there have been no further VTE episodes while receiving the IMiD plus therapeutic anticoagulation, we stop anticoagulation one to three months after these agents have been discontinued, provided that
         <strong>
         </strong>
         the patient has been receiving therapeutic anticoagulation for a minimum of three to six months and has no other indication for anticoagulation. (See
         <a class="local">
          'Diagnosis and management of VTE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2164274662">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
        </p>
        <p>
         The editors of UpToDate gratefully acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges extensive contributions of Robert A Kyle, MD to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarpace SL, Hahn T, Roy H, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 2005; 46:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streetly M, Hunt BJ, Parmar K, et al. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol 2005; 74:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakraborty R, Bin Riaz I, Malik SU, et al. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer 2020; 126:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schütt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98:1614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80:1568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108:403; author reply 404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354:2079.
          </a>
         </li>
         <li class="breakAll">
          List of lenalidomide capsule packaging. US National Library of Medicine, 2023. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=lenalidomide&amp;pagesize=20&amp;page=1 (Accessed on April 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357:2123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010; 116:5838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23:2147.
          </a>
         </li>
         <li class="breakAll">
          Label information for POMALYST-pomalidomide capsules. DailyMed, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66 (Accessed on April 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27:5008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013; 121:1961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood 2013; 121:1968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagannath S, Hofmeister CC, Siegel DS, et al. Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis (abstract 450). Blood 2012; 120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanaizi Z, Flores B, Hemmings R, et al. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2015; 20:329.
          </a>
         </li>
         <li class="breakAll">
          List of thalidomide capsule packaging. US National Library of Medicine, 2023. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=thalidomide&amp;pagesize=20&amp;page=1 (Accessed on April 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011; 9:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Facon T, Mary JY, Hulin C, et al. Randomized clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-thal), and high-dose therapy using melphalan 100 mg/m2 (MEL100) for newly-diagnosed myeloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial (abstract). Blood 2004; 104:63a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams CD, Byrne JL, Sidra G, et al. Combination chemotherapy with cyclophosphamide, thalidomide, and dexamethasone achieves a high response rate in patients with newly-diagnosed, VAD-refractory and relapsed myeloma (abstract). Blood 2004; 104:419a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 2020; 136:1091.
          </a>
         </li>
         <li class="breakAll">
          Label information for KYPROLIS carfilzomib injection. DailyMed, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6 (Accessed on April 21, 2023).
         </li>
         <li class="breakAll">
          List of bortezomib injection packaging. US National Library of Medicine, 2023. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=bortezomib&amp;pagesize=20&amp;page=1 (Accessed on April 21, 2023).
         </li>
         <li class="breakAll">
          Label information for NINLARO ixazomib capsules. DailyMed, 2023. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=ixazomib&amp;pagesize=20&amp;page=1 (Accessed on April 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piedra K, Peterson T, Tan C, et al. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol 2022; 196:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 374:1621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Kim Y. Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. Int J Hematol 2020; 112:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sborov DW, Baljevic M, Reeves B, et al. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol 2022; 199:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 2019; 94:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li A, Wu Q, Luo S, et al. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw 2019; 17:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanfilippo KM, Carson KR, Wang TF, et al. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Res Pract Thromb Haemost 2022; 6:e12634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dima D, Li A, Granat LM, et al. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol 2023; 201:280.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf (Accessed on August 10, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakraborty R, Rybicki L, Wei W, et al. Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score. Blood 2022; 140:2443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20:e566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18:2044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein U, Kosely F, Hillengass J, et al. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009; 88:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikhlaque N, Seshadri V, Kathula S, Baumann MA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol 2006; 81:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isoda A, Sato N, Miyazawa Y, et al. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide. Int J Hematol 2015; 102:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pegourie B, Karlin L, Benboubker L, et al. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol 2019; 94:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornell RF, Goldhaber SZ, Engelhardt BG, et al. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol 2020; 190:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sayar Z, Gates C, Bristogiannis S, et al. Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study. Thromb Res 2022; 213:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storrar NPF, Mathur A, Johnson PRE, Roddie PH. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol 2019; 185:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2019; 380:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366:1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1332 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19545290" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15621807" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Arterial thrombosis in four patients treated with thalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19636003" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15777340" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31913498" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094721" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613105" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14679133" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11520815" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12149193" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16342649" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16835968" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16790586" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19853510" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16696148" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lenalidomide and venous thrombosis in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16696148" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lenalidomide and venous thrombosis in multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032762" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032763" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876454" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19626046" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19626046" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249589" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19720894" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23243282" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23319574" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis (abstract 450)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25673103" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25673103" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21255254" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10564685" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Antitumor activity of thalidomide in refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637329" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506164" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327525" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15274069" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16445831" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325847" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12780791" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Thalidomide and dexamethasone for resistant multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12409330" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16365178" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16398649" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Randomized clinical trial comparing melphalan-prednisone (MP), MP-thalidomide (MP-thal), and high-dose therapy using melphalan 100 mg/m2 (MEL100) for newly-diagnosed myeloma patients aged 65-75 years. Interim analysis of the IFM 99-06 trial (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451428" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16530576" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Combination chemotherapy with cyclophosphamide, thalidomide, and dexamethasone achieves a high response rate in patients with newly-diagnosed, VAD-refractory and relapsed myeloma (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32438407" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32438407" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32438407" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32438407" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482145" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26671818" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34396516" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28017406" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21146205" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27119237" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32710431" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36111391" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31379000" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31319391" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35028491" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36604838" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36604838" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35772005" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31381464" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31492632" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23217107" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33570602" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282540" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21835953" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15470485" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16525139" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18668241" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16680743" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26177588" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30859608" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32314352" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35278887" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29785771" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30511879" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30786186" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22571201" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Lenalidomide after stem-cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22571202" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574271" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
